XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenue:        
Total revenue $ 92,274 $ 70,301 $ 164,323 $ 147,563
Operating expenses:        
Research and development 19,678 20,233 38,389 44,590
Sales and marketing 21,002 21,630 40,832 44,861
General and administrative 27,678 29,327 54,589 57,359
Restructuring costs 68 848 68 848
Total operating expenses 96,372 97,925 187,758 199,511
Loss from operations (4,098) (27,624) (23,435) (51,948)
Other income:        
Interest income, net 2,826 2,871 5,711 5,537
Change in estimated fair value of common stock warrant liability 0 3 0 10
Other expense, net (100) (271) (390) (2,245)
Total other income 2,726 2,603 5,321 3,302
Loss before income taxes (1,372) (25,021) (18,114) (48,646)
Income tax (expense) benefit (22) 68 61 (56)
Net loss $ (1,394) $ (24,953) $ (18,053) $ (48,702)
Net loss per share (Note 3):        
Basic (in dollars per share) $ (0.03) $ (0.46) $ (0.35) $ (0.91)
Diluted (in dollars per share) $ (0.03) $ (0.46) $ (0.35) $ (0.91)
Weighted-average shares used to compute net loss per share:        
Basic (in shares) 52,195,620 53,846,260 51,943,989 53,745,299
Diluted (in shares) 52,195,620 53,846,260 51,943,989 53,745,299
Testing services revenue        
Revenue:        
Total revenue $ 70,918 $ 53,414 $ 124,755 $ 115,198
Operating expenses:        
Cost of testing services, product, digital, and other 14,308 15,324 27,940 30,620
Product revenue        
Revenue:        
Total revenue 10,610 7,876 19,204 14,737
Operating expenses:        
Cost of testing services, product, digital, and other 6,245 3,926 11,589 7,992
Patient and digital solutions revenue        
Revenue:        
Total revenue 10,746 9,011 20,364 17,628
Operating expenses:        
Cost of testing services, product, digital, and other $ 7,393 $ 6,637 $ 14,351 $ 13,241